NCT01955369
Completed
Not Applicable
Amyotrophic Lateral Sclerosis Registry Rhineland-Palatinate
Klinikum Ludwigshafen1 site in 1 country200 target enrollmentOctober 2009
ConditionsAmyotrophic Lateral Sclerosis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Amyotrophic Lateral Sclerosis
- Sponsor
- Klinikum Ludwigshafen
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Death
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
There is a lack of prospective and population-based epidemiological data on amyotrophic lateral sclerosis in Germany so far. The purpose of this registry is to investigate the incidence, course and phenotypic variety of ALS in Rhineland-Palatinate, a South-West German state of about 4 million inhabitants.
Investigators
Joachim Wolf
Senior neurologist of the Dept. of Neurology
Klinikum Ludwigshafen
Eligibility Criteria
Inclusion Criteria
- •diagnosis of amyotrophic lateral sclerosis according to revised El Escorial criteria
- •minimum of 18 years
- •minimum of 6 months of residency in Rhinelnad-Palatinate
Exclusion Criteria
- •patients below 18 years
- •ALS patients outside Rhineland-Palatinate
Outcomes
Primary Outcomes
Death
Time Frame: an average of 3 years
death of participating ALS patients independent of the cause of death
Secondary Outcomes
- Tracheostomy(an average of 3 years)
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis (ALS)ALSNCT03366506Hadassah Medical Organization2,000
Recruiting
Not Applicable
A Registered Cohort Study on Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisNCT04008329First Affiliated Hospital of Fujian Medical University2,000
Not yet recruiting
Not Applicable
Amyotrophic Lateral Sclerosis RegistryAmyotrophic Lateral SclerosisNCT05892822yilong Wang1,000
Recruiting
Not Applicable
The National Amyotrophic Lateral Sclerosis RegistryAmyotrophic Lateral SclerosisNCT01772602Centers for Disease Control and Prevention30,000
Completed
Phase 1
Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral SclerosisMotor Neuron Disease, Amyotrophic Lateral SclerosisNCT03828123Bioinova, s.r.o.26